THERAKOS™ Photopheresis: more than 500,000 treatments given

THERAKOS™ Photopheresis is indicated for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that are unresponsive to other forms of treatment.

Photopheresis has also been shown to be associated with an improvement in GVHD and some of the symptoms associated with GVHD and SOT rejection.^16-23

THERAKOS™ Photopheresis has been used as a palliative therapy for CTCL for over 20 years, in over 500,000 treatments.

THERAKOS™ Photopheresis has demonstrated efficacy and safety in CTCL patients has not been associated with secondary malignancies or opportunistic infections.^3,5

Extracorporeal photopheresis (ECP) is performed using either the THERAKOS™ CELLEX™ Photopheresis System or the THERAKOS™ UVAR XTS™ Photopheresis System.